Other News To Note
Thursday, July 19, 2012
Hemispherx Biopharma Inc., of Philadelphia, said it submitted a new drug application for Ampligen for the treatment of chronic fatigue syndrome to regulatory authorities in Argentina, under its orphan drug regulations. GP Pharm SA, of Gava, Spain, is Hemispherx's partner in Argentina and is responsible for commercialization of Ampligen and Alferon N Injection, which gained regulatory approval in Argentina earlier this year for the treatment of genital warts.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.